KR20240026185A - 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도 - Google Patents

항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도 Download PDF

Info

Publication number
KR20240026185A
KR20240026185A KR1020247001972A KR20247001972A KR20240026185A KR 20240026185 A KR20240026185 A KR 20240026185A KR 1020247001972 A KR1020247001972 A KR 1020247001972A KR 20247001972 A KR20247001972 A KR 20247001972A KR 20240026185 A KR20240026185 A KR 20240026185A
Authority
KR
South Korea
Prior art keywords
ser
seq
set forth
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001972A
Other languages
English (en)
Korean (ko)
Inventor
위안 린
루 수
칸 린
청 리아오
Original Assignee
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
상하이 쉥디 파마슈티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드, 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
Publication of KR20240026185A publication Critical patent/KR20240026185A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247001972A 2021-06-28 2022-06-28 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도 Pending KR20240026185A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110722124 2021-06-28
CN202110722124.0 2021-06-28
PCT/CN2022/101780 WO2023274201A1 (zh) 2021-06-28 2022-06-28 抗cd40抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
KR20240026185A true KR20240026185A (ko) 2024-02-27

Family

ID=84690362

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001972A Pending KR20240026185A (ko) 2021-06-28 2022-06-28 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도

Country Status (11)

Country Link
US (1) US20250340661A1 (https=)
EP (1) EP4365200A4 (https=)
JP (1) JP2024523514A (https=)
KR (1) KR20240026185A (https=)
CN (1) CN117295764A (https=)
AU (1) AU2022301422A1 (https=)
BR (1) BR112023026111A2 (https=)
CA (1) CA3223842A1 (https=)
MX (1) MX2023015070A (https=)
TW (1) TW202309095A (https=)
WO (1) WO2023274201A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途
WO2024140903A1 (zh) 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP4202127B2 (ja) * 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
BR112012024713B1 (pt) * 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
HUE065915T2 (hu) * 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
WO2017040932A1 (en) * 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CR20180177A (es) * 2015-09-30 2018-06-22 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
CN110546164B (zh) * 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
MX2019014375A (es) * 2017-06-01 2020-01-23 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
CN111454362B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 特异结合cd40的抗体及其用途

Also Published As

Publication number Publication date
EP4365200A1 (en) 2024-05-08
MX2023015070A (es) 2024-01-17
US20250340661A1 (en) 2025-11-06
WO2023274201A1 (zh) 2023-01-05
CA3223842A1 (en) 2023-01-05
AU2022301422A1 (en) 2024-02-01
CN117295764A (zh) 2023-12-26
BR112023026111A2 (pt) 2024-03-05
EP4365200A4 (en) 2025-04-09
JP2024523514A (ja) 2024-06-28
TW202309095A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
JP7705873B2 (ja) Ｐｖｒｉｇ結合タンパク質及びその医薬用途
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
JP2022502076A (ja) 抗ｔｎｆｒ２抗体およびその使用
US20210009706A1 (en) Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN120737200A (zh) 抗人nr1抗体衍生物
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
US20250340661A1 (en) Anti cd40 antibody, antigen binding fragment and medical use thereof
JP2026502840A (ja) Ｃｄ４０結合分子の組成物及び医薬的使用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
CN118684772A (zh) 抗4-1bb的激动型抗体及其应用
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application